المؤلفون: Borghaei H; Hematology and Oncology Department, Fox Chase Cancer Center, Philadelphia, USA. Electronic address: Hossein.Borghaei@fccc.edu., de Marinis F; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy., Dumoulin D; Department of Pulmonary Medicine, Erasmus Medisch Centrum, Rotterdam, the Netherlands., Reynolds C; Ocala Cancer Center, Florida Cancer Specialists and Research Institute - North Region (SCRI), Ocala, USA., Theelen WSME; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Percent I; North Port Cancer Center, Florida Cancer Specialists and Research Institute - South Region (SCRI), Port Charlotte, USA., Gutierrez Calderon V; Department of Medical Oncology, Hospital Regional Universitario de Málaga, Málaga, Spain., Johnson ML; Department of Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, USA., Madroszyk-Flandin A; Department of Medicine, Institut Paoli-Calmettes, Marseille, France., Garon EB; Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles., He K; Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, USA., Planchard D; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France., Reck M; Department of Thoracic Oncology, LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany., Popat S; Lung Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK., Herbst RS; Section of Medical Oncology, Yale University, New Haven., Leal TA; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta., Shazer RL; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA., Yan X; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA., Harrigan R; Department of Clinical Research and Development, Mirati Therapeutics, Inc., San Diego, USA., Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

مؤلفون مشاركون: SAPPHIRE Investigators

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Jan; Vol. 35 (1), pp. 66-76. Date of Electronic Publication: 2023 Oct 20.

نوع المنشور: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/pathology , Lung Neoplasms*/pathology , Anilides* , Pyridines*, Humans ; Docetaxel/therapeutic use ; Nivolumab/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Tumor Microenvironment